Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.66 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062600 | 0.85 | POLB (0.49) | POLBCYP11B1CYP11B2MAPTALDH1A1 | |
| SCHEMBL3052125 | 0.83 | ALDH1A1 (0.65) | POLBMAPTALDH1A1KMT2ASMN1; SMN2 | |
| 4-Nitrophenyl Phenylcarbamate SCHEMBL1434931 | 0.83 | ALDH1A1 (0.62) | POLBMAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL241619 | 0.82 | NPC1 (0.63) | MAPTALDH1A1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3573967 | 0.81 | MAPT (0.66) | POLBMAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL8373850 | 0.81 | KMT2A (0.75) | POLBCYP11B1CYP11B2MAPTALDH1A1 | |
| SCHEMBL13527385 | 0.81 | KMT2A (0.52) | POLBMAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7371634 | 0.80 | CYP11B1 (1.00) | POLBCYP11B1CYP11B2MAPTALDH1A1 | |
| SCHEMBL12694410 | 0.80 | MEN1 (0.63) | POLBMAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4631425 | 0.79 | ALDH1A1 (0.56) | POLBMAPTALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | disclosed |
| WO-2012164085-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-12-06 | — | — | WO | disclosed |
| EP-2197552-B1 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2197552-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009037001-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-5276168-A | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents | E. R. SQUIBB & SONS, INC. (US) | 1994-01-04 | — | — | US | disclosed |
| EP-0462761-A2 | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents | E.R. SQUIBB & SONS, INC. (US) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | POLB 1365/4885CYP11B1 1492/4885CYP11B2 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.